OptiBiotix Health PLC Presentation of research data at ProBiota 2017

TIDMOPTI

OptiBiotix Health PLC

12 January 2017

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Presentation of research data at European Conference: ProBiota 2017

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has had two abstracts accepted for presentation at ProBiota 2017 in Berlin from 1-3 February 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries. The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients market.

The two abstracts relate to the work the Company has undertaken on its cholesterol lowering probiotic. The first abstract will cover the results of the clinical study and will be presented as a poster and oral presentation. The second abstract will be presented as a poster and covers the work on species specific microbiome modulators which the Company has used to enhance the cholesterol reducing effect of their cholesterol reducing strain (LP-LDL(R)). In the case of this strain, it leads to a threefold increase in the strains ability to lower cholesterol.

Commenting, Stephen O'Hara, CEO of OptiBiotix said: "These publications, at a major conference, will support the launch of a range of cardiovascular products to reduce LDL cholesterol, blood pressure and cardiovascular risk, planned for the spring of 2017. The publications will provide the scientific evidence for sales and marketing literature, which will help with product differentiation and higher margins. In order to provide us with wider coverage of our scientific advances in both the scientific and mainstream news media, we have appointed a specialist scientific PR company, Vane Percy & Roberts to help with this."

For further information, please contact:

 
 OptiBiotix Health plc                                                    www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                        Contact via Walbrook 
                                                                                       below 
 
 Cairn Financial Advisers LLP (NOMAD)                                          Tel: [phone] 
                                                                                        0883 
 Liam Murray 
 
 finnCap (Broker)                                                              Tel: [phone] 
                                                                                        0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                           Tel: [phone] or [e-mail] 
 Anna Dunphy                                                              Mob: 07876 
                                                                            741 001 
 
 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASFFFMFFWSEFF

(END) Dow Jones Newswires

January 12, 2017 02:00 ET (07:00 GMT)